Valuation: Theracryf Plc

Market Cap 6.2M 5.44M 5.04M 4.63M 8.77M 593M 8.94M 60.03M 23.55M 291M 23.28M 22.77M 1.01B P/E 2026 *
-1.45x
P/E 2027 * -1.77x
Enterprise Value 4.05M 3.55M 3.29M 3.03M 5.73M 388M 5.84M 39.21M 15.38M 190M 15.21M 14.87M 657M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 month-8.51%
3 months+10.26%
6 months+2.38%
Current year+7.50%
1 week 0.21
Extreme 0.21
0.22
1 month 0.21
Extreme 0.21
0.25
Current year 0.18
Extreme 0.182
0.27
1 year 0.18
Extreme 0.175
0.3
3 years 0.18
Extreme 0.175
3.4
5 years 0.18
Extreme 0.175
9
10 years 0.18
Extreme 0.175
35
Manager TitleAgeSince
Chief Executive Officer 64 30/09/2020
Director of Finance/CFO - 04/09/2023
Chief Tech/Sci/R&D Officer - 30/04/2021
Director TitleAgeSince
Director/Board Member - 13/10/2015
Director/Board Member 64 30/09/2020
Director/Board Member - 31/12/2023
Date Insider Type Main position Quantity % Market Cap.
15/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
21/05/25Others

Director

422,727,272 19.8499%
03/03/25Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-15.69%-92.46% 6.2M
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-5.63%-2.01%+7.27%+421.22% 25.06B
-0.80%-3.42%-18.27%-17.16% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-1.21%+0.30%+22.19%+187.83% 14.2B
Average -1.55%-0.74%+42.13%+167.82% 24.16B
Weighted average by Cap. -1.76%-1.56%+47.66%+166.00%

Financials

2026 *2027 *
Net sales - -
Net income -3.35M -2.94M -2.72M -2.5M -4.74M -321M -4.83M -32.45M -12.73M -158M -12.58M -12.31M -544M -3.43M -3.01M -2.79M -2.56M -4.85M -328M -4.94M -33.21M -13.02M -161M -12.88M -12.6M -557M
Net Debt -2.15M -1.89M -1.75M -1.61M -3.04M -206M -3.1M -20.83M -8.17M -101M -8.08M -7.9M -349M 453K 398K 368K 339K 641K 43.4M 654K 4.39M 1.72M 21.31M 1.7M 1.67M 73.61M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
13/07/26 GBX 0.2150 0.00% 3,333
10/07/26 GBX 0.2150 0.00% 243,057
09/07/26 GBX 0.2150 0.00% 2,037,924
08/07/26 GBX 0.2150 0.00% 0
07/07/26 GBX 0.2150 0.00% 554,117
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002885USD
Average target price
0.0431USD
Spread / Average Target
+1,395.17%

Annual profits - Rate of surprise